What Is Off-Label Drug Use?

If you have ever taken a medication for a condition that isn't listed on its label, you have experienced off-label prescribing — a practice that is far more common than most patients realize. Off-label drug use is legal, often evidence-based, and in many fields of medicine, it represents the standard of care. Understanding what off-label prescribing means, why it happens, and how to evaluate whether it is appropriate for you is important knowledge for any patient.

What Does "Off-Label" Mean?

When the FDA approves a drug, it approves it for a specific indication (medical condition), specific patient population (adults vs. children, certain age ranges), specific dose range, and specific route of administration — all based on the clinical trial data submitted by the manufacturer.

Off-label use occurs whenever a physician prescribes a drug for a use not included in the FDA-approved prescribing information. This includes:

• Using a drug for a different condition than the one it was approved for
• Using it in a different patient population (e.g., using an adult-approved drug in children)
• Using it at a different dose than approved
• Using it via a different route of administration
• Using it for a different duration than studied

It does NOT mean the use is illegal, experimental, or inappropriate. The FDA regulates drug approval and marketing — it does not regulate the practice of medicine. Once a drug is approved, physicians have broad legal authority to prescribe it as they judge clinically appropriate.

How Common Is Off-Label Prescribing?

Extremely common. Studies estimate that 20–60% of all prescriptions in certain specialties are for off-label uses. In oncology, psychiatry, neurology, and pediatrics, off-label prescribing is especially prevalent — often because clinical trial evidence in those specific populations is limited, because diseases evolve faster than regulatory approval, or because combination therapies with substantial evidence have not been formally approved as a combination.

A landmark study published in JAMA found that approximately 21% of all prescriptions written for common medications were for off-label uses, and only about 27% of those had strong scientific evidence supporting them.

Why Does Off-Label Prescribing Happen?

Clinical evidence precedes regulatory approval: Clinical evidence accumulates through research, and that evidence often supports uses that the manufacturer never formally sought approval for — either because pursuing additional approvals is expensive, because the market is too small to justify the investment, or because the evidence emerged from academic studies rather than manufacturer-sponsored trials.

Pediatric medicine: Many drugs have never been tested in children — historically, children were excluded from most clinical trials. Pediatricians routinely use adult-approved drugs at adjusted doses. The FDA has incentivized more pediatric drug studies through the Pediatric Research Equity Act and Best Pharmaceuticals for Children Act, but large gaps remain.

Rare diseases: Drugs for rare conditions (orphan diseases) may lack the large population necessary to conduct full trials for every conceivable use. Physicians treating patients with rare diseases often rely on case series, expert opinion, and analogical reasoning.

Cancer treatment: New cancer drugs may be approved for one cancer type based on a genetic mutation or pathway shared across multiple cancers. Using them in other cancer types sharing the same biology — a concept called "tumor-agnostic" prescribing — is common and increasingly supported by basket trial evidence. Additionally, combination regimens often include off-label combinations.

Psychiatric medications: Many psychiatric medications have demonstrated efficacy for conditions beyond their primary approval. Gabapentin, approved for epilepsy and postherpetic neuralgia, is widely prescribed off-label for anxiety, alcohol withdrawal, restless legs syndrome, and chronic pain. Quetiapine, approved for schizophrenia and bipolar disorder, is frequently prescribed off-label for insomnia, PTSD, and anxiety — with significant controversy about the evidence base.

Symptom management: Drugs may be used off-label for symptom management in palliative or supportive care settings where formal approval would never be sought.

Examples Of Well-Established Off-Label Uses

Some of the most common and well-supported off-label uses include:

Aspirin: Approved as an analgesic; its off-label use for cardiovascular disease prevention and primary prevention of colorectal cancer is supported by decades of evidence (though the risk-benefit balance for primary prevention has evolved).

Propranolol (beta-blocker): Used off-label for performance anxiety, migraine prevention, essential tremor, and hyperthyroid symptoms — all with strong evidence.

Amitriptyline (tricyclic antidepressant): Approved for depression; widely used off-label for neuropathic pain, migraine prevention, interstitial cystitis, and insomnia at doses far lower than antidepressant doses.

Gabapentin: Approved for epilepsy and postherpetic neuralgia; off-label for neuropathic pain (fibromyalgia, diabetic neuropathy), alcohol withdrawal, and restless legs syndrome.

Topiramate: Approved for epilepsy and migraine prevention; off-label for weight loss and alcohol use disorder.

Metformin: Approved for type 2 diabetes; off-label use for polycystic ovary syndrome (PCOS) and prediabetes is widespread and supported by evidence.

Minoxidil: Originally approved as an oral antihypertensive; the topical formulation is approved for androgenetic alopecia; oral low-dose minoxidil for hair loss is an emerging but widely practiced off-label use.

Rituximab: Approved for certain lymphomas and autoimmune conditions; used off-label for many other autoimmune diseases (neuromyelitis optica, myasthenia gravis, pemphigus) with substantial evidence.

Sildenafil (Viagra): Approved for erectile dysfunction and pulmonary arterial hypertension; used off-label for altitude sickness prevention, Raynaud's phenomenon, and female sexual dysfunction.

The Controversy: When Off-Label Use Is Problematic

Not all off-label prescribing is equally well-supported. The spectrum ranges from off-label uses with overwhelming evidence to those with minimal evidence and significant potential harm.

Gabapentin for insomnia: While commonly prescribed, the evidence base is weak and risks of dependence are increasingly recognized.

Antipsychotics for dementia agitation: Widely used off-label but associated with increased mortality in elderly patients with dementia; black box warnings were added to all antipsychotics for this use.

Opioids for chronic non-cancer pain: Underwent massive off-label expansion in the 1990s and 2000s with inadequate evidence — contributing directly to the opioid epidemic.

Hormone therapy for menopausal symptoms in women with cardiovascular risk: Was widely prescribed before the Women's Health Initiative found unexpected cardiovascular and cancer risks.

What Patients Should Know And Do

Ask whether a prescription is off-label: You have the right to know. Ask: "Is this an approved use of this medication, or are you prescribing it for a different purpose?"

Ask about the evidence: "What evidence supports using this medication for my condition?"

Ask about alternatives: "Are there FDA-approved treatments for my condition? Why is this one preferable?"

Ask about risks: Off-label uses may not have the same safety data as approved uses. What are the known risks for this specific application?

Informed consent: For significant off-label uses — particularly experimental applications or those with significant risk — informed consent should explicitly address the off-label nature of the treatment.

Insurance coverage: Insurance companies sometimes decline to cover off-label prescriptions. Your physician can often support coverage with a letter of medical necessity citing published evidence.

Conclusion

Off-label drug use is a legitimate, legal, and often evidence-supported practice that represents a substantial proportion of modern medical prescribing. It fills gaps where formal regulatory approval hasn't followed the evidence, serves patient populations excluded from original trials, and enables responsive, individualized care. The critical question is always whether the off-label use is supported by sufficient evidence and whether the benefit-to-risk ratio is favorable for your specific situation — which is exactly the same question that should be asked of any medical treatment, on-label or off.